Examining the role of oxytocin in the interoceptive effects of 3,4‐methylenedioxymethamphetamine (MDMA, ‘ecstasy’) using a drug discrimination paradigm in the rat
Jillian H. Broadbear, Brendan J. Tunstall, Katherine Beringer
Addiction Biology November 11, 2010 DOI: 10.1111/j.1369-1600.2010.00267.x via OpenAlex
Summary
AI-generated from the abstractMDMA produces prosocial mood changes by enhancing serotonin transmission, which can stimulate oxytocin release. In a drug discrimination experiment with 24 male and female rats, an oxytocin analog partially mimicked MDMA's effects, while an oxytocin receptor blocker selectively reduced responses to MDMA but not to amphetamine. Imipramine had no effect. Oxytocin receptor activation appears to be a key cue distinguishing MDMA from amphetamine.
Study at a glance
| Characteristics | Drug discrimination paradigm Peer reviewed |
|---|---|
| Sample size | 24 |
| Population | Male and female Sprague Dawley rats |
| Interventions | carbetocin atosiban imipramine |
| Topics | MDMA Serotonin |
| Keywords | Oxytocin receptor Psychology Amphetamine Hallucinogen |
| Citations | 38 |
| Key finding | Oxytocin receptor activation is a key MDMA-specific interoceptive cue that distinguishes it from amphetamine in rats. |
Abstract
ABSTRACT 3,4‐Methylenedioxymethamphetamine (MDMA, ‘ecstasy’) use results in distinctive mood changes of a prosocial nature, most likely through its enhancement of serotonin (5HT) neurotransmission. Activation of 5HT‐1A postsynaptic receptors has been shown to stimulate the release of oxytocin in the central nervous system where it regulates aspects of mood and behavior. Using a drug discrimination paradigm, we examined whether modulation of oxytocin receptor activity would affect conditioned behavioral responses to MDMA. Male and female Sprague Dawley rats ( n = 24) were trained to reliably differentiate between MDMA and a related stimulant, amphetamine (AMP), and saline using a three‐lever drug discrimination paradigm. The extent to which substitution with carbetocin (an oxytocin analog) or co‐administration with atosiban (an oxytocin receptor antagonist) affected drug‐appropriate responding was evaluated. The tricyclic antidepressant imipramine was included as a negative control. The results supported the hypotheses that substitution with an oxytocin analog (carbetocin) would partially generalize to the MDMA training cue, whereas blocking oxytocin receptors with atosiban would result in a selective disruption of MDMA––but not AMP‐appropriate responding. These findings were specific to the oxytocin receptor ligands as imipramine pre‐treatment did not affect drug‐appropriate responding. The results of this study implicate oxytocin receptor activation as a key MDMA‐specific interoceptive cue in male and female rats and support the conclusion that this is one of the features of MDMA's subjective effects that distinguishes it from AMP.